Henriet A-C, Marchand-Adam S, Mankikian J, Diot P
Inserm U618, Service de Pneumologie, Hôpital Bretonneau, CHU de Tours, 2 Boulevard Tonnellé, 37044 Tours, France.
Rev Mal Respir. 2010 Dec;27(10):1141-9. doi: 10.1016/j.rmr.2010.10.024. Epub 2010 Nov 18.
In COPD, inhaler choice should be based on the likelihood that the patient will be able to use the device correctly in order to favour adherence and compliance, and therefore treatment efficacy. SATE OF THE ART: Performances of usual inhalers are limited by the necessity of a good coordination of patient inspiration and inhaler activation (pressurized metered dose inhalers), or a sufficient inspiratory flow (dry powder inhalers). Respimat®, the first "Soft Mist™ inhaler" (SMI), releases the drug solution as a low and sustained soft mist, so that lung deposition is both improved and reproducible.
In clinical studies, Respimat® has been shown to allow equivalent bronchodilator response and tolerability to metered dose or dry powder inhalers, but with lower doses of active drugs. Furthermore, studies assessing inhaler preference in COPD showed that patients preferred Respimat® to usual inhalers.
Respimat® SMI offers new perspectives for the management of chronic respiratory diseases, particularly in newly diagnosed or poorly compliant patients.
在慢性阻塞性肺疾病（COPD）中，吸入器的选择应基于患者能够正确使用该装置的可能性，以促进依从性和顺应性，从而提高治疗效果。
常用吸入器的性能受到患者吸气与吸入器启动（压力定量吸入器）良好协调的必要性或足够的吸气流速（干粉吸入器）的限制。Respimat®，首款“软雾吸入器”（SMI），将药物溶液以低流量且持续的软雾形式释放，从而改善并可重复肺部沉积。
在临床研究中，Respimat®已显示出与定量吸入器或干粉吸入器具有同等的支气管扩张反应和耐受性，但所需活性药物剂量更低。此外，评估COPD患者对吸入器偏好的研究表明，患者更喜欢Respimat®而非常用吸入器。
Respimat®软雾吸入器为慢性呼吸道疾病的管理提供了新的前景，特别是在新诊断或依从性差的患者中。
